Xtant Medical Holdings reported a $3.6 million net loss for the third quarter of 2026, marking its second consecutive quarter missing financial guidance. Consequently, the company has withdrawn its full-year 2026 outlook and initiated a board-led strategic review to explore potential partnerships, financings, or business combinations to maximize stockholder value.
Xtant reported its second consecutive quarter missing guidance, withdrew full-year 2026 guidance, swung to a $3.6 million net loss from a $1.3 million profit a year earlier, and saw revenue fall to $24.3 million from $33.3 million. Gross margin dropped to 56.3% from 66.1% and cash fell to $7.8 million from $17.1 million. The board-led strategic review offers possible speculative upside, but the hard fundamentals are negative.
- ▼ Second consecutive quarter missing guidance and full-year 2026 guidance withdrawn
- ▼ Net loss of $3.6 million ($0.03/share) vs net income of $1.3 million in Q3 2025
- ▲ Biologics revenue grew 13% year-over-year to $19.3 million, including $2.2 million from HEMOBLAST Bellows
- ▲ Strategic review could produce a value-maximizing transaction, though no timetable or assurance of outcome is given